arrow_back Back to App

Limiting Patents in Drug and Biological Product Infringement Actions.

New rules limit the number of patents pharmaceutical companies can assert in lawsuits concerning generic drugs and biosimilar products. This aims to facilitate the market entry of cheaper alternatives, potentially lowering drug costs for citizens and increasing accessibility. The changes apply to applications submitted on or after the enactment date.
Key points
Companies suing for patent infringement on drugs or biological products can only assert one patent per patent group in a single action.
The limitation aims to reduce "patent thickets" that hinder the market entry of more affordable drug alternatives.
Potentially lower drug prices and greater accessibility for patients due to faster introduction of generics and biosimilars.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 118_HR_6986
Sponsor: Rep. Arrington, Jodey C. [R-TX-19]
Process start date: 2024-01-12
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

To address patent thickets.

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 118_HR_6986.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2024-01-12.

What are the main provisions?

Key points include:

  • Companies suing for patent infringement on drugs or biological products can only assert one patent per patent group in a single action.
  • The limitation aims to reduce "patent thickets" that hinder the market entry of more affordable drug alternatives.
  • Potentially lower drug prices and greater accessibility for patients due to faster introduction of generics and biosimilars.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Arrington, Jodey C. [R-TX-19].

What is the latest detailed status?

The latest detailed status is: Referred to the House Committee on the Judiciary.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-25.

CATEGORIES

Health Courts and Law Economy